Search results for "slas europe 2018"
Selected Filters:
Vote for the Best New Life Sciences Product in the 2021 Scientists’ Choice Awards
For a chance to win a $500/£400/450€ Amazon Gift Card, cast your vote for the new product which has made the most difference to your research
Join the SelectScience Virtual Summit on Cancer and Immunology Research 2020 - May 11-13
Register today to reserve a place at the Summit - it opens at 13:00 (BST) / 14:00 (CEST) / 08:00 (EDT) / 05:00 (PDT) on Monday, May 11
Bruker BioSpin Wins European Video of the Year
8th Annual Meeting of the European Sepsis Alliance
European LC-MS/MS Clinical Laboratory Virtual Day
Qureight’s 3D AI imaging platform to support Calluna Pharma’s Phase 2 IPF Trial of CAL101 in idiopathic pulmonary fibrosis
CAL101 is a first-in-class monoclonal antibody that neutralises the S100A4 protein, which is an upstream driver and amplifier of the multiple pro-fibrotic pathways active in IPF
FuGENE® 4K Transfection Reagent
Promega Corp.A best-in-class DNA transfection reagent for your research.
HemoCue® Glucose 201 System
HemoCueProviding lab accuracy and ease of use, the HemoCue 201 System has become a standard in Glucose point-of-care testing. Allows you to accurately measure blood glucose levels to aid in the diagnosis and monitoring of diabetes.
Ncardia
Ncardia develops, produces and commercializes highly predictive human cellular assay systems for safety and efficacy testing. The product portfolio encompasses a broad panel of hiPSC derived cryopreserved cardiomyocytes and neurons. In addition, the company delivers the CardioPlateTM product line of quality controlled ready to use assay plates. Using its cell products, Ncardia develops and provides its customers with a broad portfolio of cardiovascular services from safety pharmacology and disease modeling to cardiovascular drug efficacy screening. Ncardia is based in Belgium, The Netherlands, Germany, and the USA. The company is privately held and was established in September 2017 following the merger of Pluriomics and Axiogenesis, two well-known pioneers in the field of stem cell derived cells for safety and toxicology assessment.
Atrandi Biosciences
Atrandi Biosciences, founded in 2016, is a pioneering life sciences tool company transforming single-cell analysis with its patented Semi-Permeable Capsule (SPC) technology. This next-generation technology isolates tens of thousands of single cells within discrete, permeable compartments, allowing bulk reactions to proceed as usual while preserving single-cell resolution. SPCs have already unlocked previously inaccessible applications, such as high-throughput microbial and eukaryotic genomics, and are poised to enable true single-cell multiomics. Headquartered in Vilnius, Lithuania, Atrandi’s name, meaning “you discover” in Lithuanian, embodies the company’s mission to empower scientists to uncover the unknown and make groundbreaking discoveries. Company Facts: 200+ satisfied customers 150+ install base 20+ collaborations worldwide 65 employees and growing ISO 9001 & ISO 14001 certified



















